Cardiovascular disease burden in patients with urological cancers: The new discipline of uro-cardio-oncology

Yi Zheng, Ying Liu, Ziliang Chen, Yunpeng Zhang, Zuo Qi, Ning Wu, Zhiqiang Zhao, Gary Tse, Yong Wang, Hailong Hu, Yuanjie Niu, Tong Liu

Research output: Contribution to journalReview articlepeer-review

Abstract

Cancer remains a major cause of mortality worldwide, and urological cancers are the most common cancers among men. Several therapeutic agents have been used to treat urological cancer, leading to improved survival for patients. However, this has been accompanied by an increase in the frequency of survivors with cardiovascular complications caused by anticancer medications. Here, we propose the novel discipline of uro-cardio-oncology, an evolving subspecialty focused on the complex interactions between cardiovascular disease and urological cancer. In this comprehensive review, we discuss the various cardiovascular toxicities induced by different classes of antineoplastic agents used to treat urological cancers, including androgen deprivation therapy, vascular endothelial growth factor receptor tyrosine kinase inhibitors, immune checkpoint inhibitors, and chemotherapeutics. In addition, we discuss possible mechanisms underlying the cardiovascular toxicity associated with anticancer therapy and outline strategies for the surveillance, diagnosis, and effective management of cardiovascular complications. Finally, we provide an analysis of future perspectives in this emerging specialty, identifying areas in need of further research.

Original languageEnglish
Article numbere108
JournalCancer Innovation
Volume3
Issue number2
DOIs
Publication statusPublished - Apr 2024

Keywords

  • anticancer therapy
  • cardiovascular toxicity
  • mechanism
  • multidisciplinary management
  • urological cancer

Fingerprint

Dive into the research topics of 'Cardiovascular disease burden in patients with urological cancers: The new discipline of uro-cardio-oncology'. Together they form a unique fingerprint.

Cite this